
A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC)



APC antigen-presenting cell	HNSCC head and neck squamous cell cancer	NK neutral killer	ORR objective response rate	
CPS combined positive score	iRECIST Immune Response Evaluation	PD progressive disease	OS overall survival	
DC dendritic cell	Criteria In Solid Tumors	PD-L1Programmed Death ligand-1	TEAE treatment-emergent adverse event	
ECOG Eastern Cooperative Oncology Group	LAG-3 Lymphocyte Activation gene-3	Pts patients		
FoT end of treatment	MHC Major Histocompatibility Complex	PES_propression-free suppival		

Estimated study completion: January 2025